https://www.selleckchem.com/products/gdc-0994.html
We aimed to study the feasibility and tolerability of a combination therapy consisting of glutamic acid decarboxylase (GAD-alum), Etanercept and vitamin D in children and adolescents with newly diagnosed with type 1 diabetes (T1D), and evaluate preservation of beta cell function. Etanercept Diamyd Combination Regimen is an open-labelled multi-centre study pilot trial which enrolled 20 GAD antibodies positive T1D patients (7 girls and 13 boys), aged (mean±SD) 12.4±2.3(8.3-16.1)years, with a diabetes duration of 81.4±22.1days. Baseline f
Like
Comment
Share
